Objective
Dendritic cell (DC) immune-biology has enormous potential for development of new immunotherapies for cancer and infectious disease. Europe possesses a critical mass of leaders in the field who have pioneered many innovative advances and provided initial pr oof of principle for the approach. This NoE, DC-THERA, will integrate the activities of 25 participant groups of scientists and clinicians and 6 high quality SMEs across Europe. It will incorporate additional groups, particularly from future member states, as Associated Members of the Network Their collective expertise and resources will be forged into an ambitious Joint Programme of Activities to restructure the field. It will translate genomic, proteomic and bioinformatic information, with knowledge from molecular cell biology and pre-clinical models, into therapeutic endpoints: clinical trials of DC-based therapies for cancer and HIV. Towards this end, four thematic S&T Clusters have been defined, with a fifth for horizontal activities. The latter inc ludes development of synergistic links with other Networks, providing added value to EC Programmes by underpinning all projects developing new vaccine strategies for major killer diseases. The Network will implement an IT-based integrated knowledge managem ent system and provide a centralised European resource of databases for the field. DC-THERA will develop new research tools, integrate existing and new technological platforms, recruit additional support staff, and make these available as shared resources for all partners It will implement an ambitious Education and Training Programme, including new PhD studentships, a Visiting Scholars Scheme, high quality training courses, and a postgraduate degree in translational DC immunobiology. DC-THERA will contribu te to the European biotechnology sector and have a major impact on European policy-making for the future. DC-THERA will evolve itself into a Centre of Excellence for DC Biology,with a lasting and global impact.
Fields of science
Not validated
Not validated
- medical and health scienceshealth sciencesinfectious diseasesRNA virusesHIV
- medical and health sciencesbasic medicineimmunologyautoimmune diseases
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
- medical and health sciencesclinical medicineoncology
- medical and health sciencesbasic medicineimmunologyimmunotherapy
Keywords
Call for proposal
FP6-2003-LIFESCIHEALTH-I
See other projects for this call
Funding Scheme
NoE - Network of ExcellenceCoordinator
OXFORD
United Kingdom
See on map
Participants (31)
NIJMEGEN
See on map
LONDON
See on map
MILAN
See on map
OXFORD
See on map
BRUSSELS
See on map
SIENA
See on map
MILAN
See on map
DURHAM, NC
See on map
MILANO
See on map
PARIS
See on map
BRUSSELS
See on map
FIRENZE
See on map
STOCKHOLM
See on map
LEIDEN
See on map
MARSEILLE
See on map
MILAN
See on map
BERLIN
See on map
LONDON
See on map
BELLINZONA
See on map
ZURICH
See on map
BRUSSELS
See on map
MUENCHEN
See on map
VILLEJUIF
See on map
MILAN
See on map
MARTINSRIED
See on map
ROZZANO, MILAN
See on map
ERLANGEN
See on map
PARIS
See on map
ROME
See on map
BRUXELLES
See on map
PARIS
See on map